
Alumis Inc (ALMS) Stock Forecast & Price Target
Alumis Inc (ALMS) Analyst Ratings
Bulls say
Alumis is positioned for potential success with its two TYK2 inhibitors, envudeucitinib and A-005, due to their promising clinical data and potential for treating a wide range of diseases, including psoriasis and lupus. The company's recent announcement to file an NDA for envudeucitinib in psoriasis in the fourth quarter of 2026 is a positive sign for investors and could lead to potential market approval and revenue growth. The company's financials, including a price target of $40 based on probability-adjusted modeling and a strong pipeline of potential catalysts, suggest a positive outlook on the stock's potential. However, the company will face competition from other oral treatments and will need to provide clear clinical advantages for its drugs to stand out in the market.
Bears say
Alumis is facing significant commercialization risks as its potential target indications and products may not be as large as projected due to competitive pressures from other oral therapies and lower-than-expected switching from marketed products. The company's two TYK2 inhibitors may face challenges in terms of market penetration and commercialization due to the dominance of approved biologics in the systemic targeted therapies market for psoriasis and SLE, as well as the established presence of large pharmaceutical companies. The stock has a negative valuation due to potential regulatory risks and the company's need to prove that its products, specifically envudeucitinib in psoriasis, can compete in a crowded and challenging market.
This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.
Alumis Inc (ALMS) Analyst Forecast & Price Prediction
Start investing in Alumis Inc (ALMS)
Order type
Buy in
Order amount
Est. shares
0 shares